PL3891156T3 - Nowe krystaliczne formy inhibitora MCL-1, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne - Google Patents
Nowe krystaliczne formy inhibitora MCL-1, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczneInfo
- Publication number
- PL3891156T3 PL3891156T3 PL19817229.8T PL19817229T PL3891156T3 PL 3891156 T3 PL3891156 T3 PL 3891156T3 PL 19817229 T PL19817229 T PL 19817229T PL 3891156 T3 PL3891156 T3 PL 3891156T3
- Authority
- PL
- Poland
- Prior art keywords
- thienopyrimidine
- mcl
- inhibitor
- crystalline forms
- new crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634 | 2018-12-06 | ||
| PCT/EP2019/083773 WO2020115183A1 (en) | 2018-12-06 | 2019-12-05 | New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3891156T3 true PL3891156T3 (pl) | 2024-05-13 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19817229.8T PL3891156T3 (pl) | 2018-12-06 | 2019-12-05 | Nowe krystaliczne formy inhibitora MCL-1, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12129261B2 (pl) |
| EP (1) | EP3891156B1 (pl) |
| JP (1) | JP7649241B2 (pl) |
| KR (1) | KR102855345B1 (pl) |
| CN (1) | CN113166169A (pl) |
| AR (1) | AR117255A1 (pl) |
| AU (1) | AU2019391329B2 (pl) |
| BR (1) | BR112021010072A2 (pl) |
| CA (1) | CA3121363A1 (pl) |
| DK (1) | DK3891156T3 (pl) |
| EA (1) | EA202191534A1 (pl) |
| ES (1) | ES2971258T3 (pl) |
| FI (1) | FI3891156T3 (pl) |
| HR (1) | HRP20240211T1 (pl) |
| HU (1) | HUE065266T2 (pl) |
| IL (1) | IL283656B2 (pl) |
| LT (1) | LT3891156T (pl) |
| MA (1) | MA54379B1 (pl) |
| MD (1) | MD3891156T2 (pl) |
| MX (1) | MX2021006702A (pl) |
| PL (1) | PL3891156T3 (pl) |
| PT (1) | PT3891156T (pl) |
| RS (1) | RS65047B1 (pl) |
| SI (1) | SI3891156T1 (pl) |
| TW (1) | TWI905090B (pl) |
| WO (1) | WO2020115183A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 CA CA3121363A patent/CA3121363A1/en active Pending
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/en not_active Ceased
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 MD MDE20210991T patent/MD3891156T2/ro unknown
- 2019-12-05 KR KR1020217020808A patent/KR102855345B1/ko active Active
- 2019-12-05 AU AU2019391329A patent/AU2019391329B2/en active Active
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/en active Active
- 2019-12-05 JP JP2021531796A patent/JP7649241B2/ja active Active
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 IL IL283656A patent/IL283656B2/en unknown
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 TW TW108144437A patent/TWI905090B/zh active
- 2019-12-05 US US17/295,521 patent/US12129261B2/en active Active
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
-
2024
- 2024-09-24 US US18/894,074 patent/US20250011337A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263824A (en) | Crystals in solid form in the presence of an inhibitor | |
| ZA201903093B (en) | Crystalline forms of a magl inhibitor | |
| ES3065214T3 (en) | Crystalline forms of a btk inhibitor | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| IL240277B (en) | Solid forms of a selective inhibitor of cdk4/6 | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| SG11202103804TA (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| HUE065266T2 (hu) | Egy tienopirimidin új kristályos formái MCL-1 inhibitorként | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| IL259982A (en) | Crystalline forms of thienopyrimidine compound | |
| ZA202007034B (en) | The crystalline forms of a compound | |
| IL292847A (en) | Crystalline forms of magl inhibitor | |
| IL279953A (en) | Crystal forms of LTA4H inhibitor | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| IL259981A (en) | Crystalline forms of hydrochloride salts of thienopyrimidine compound | |
| SG11202106561RA (en) | Crystalline forms of a par4 inhibitor | |
| HK40015194A (en) | Crystalline forms of a jak inhibitor compound | |
| GB201915908D0 (en) | Crystalline forms of entrectinib | |
| EP3256481A4 (en) | Novel crystalline form of a proteasome inhibitor |